Gotowe bibliografie tematyczne / Prostate – Hypertrophy

Gotowa bibliografia na temat „Prostate – Hypertrophy”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 3 lutego 2022

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Prostate – Hypertrophy”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Prostate – Hypertrophy"

1

Viennois, Emilie, Teresa Esposito, Julie Dufour, Aurélien Pommier, Stephane Fabre, Jean-Louis Kemeny, Laurent Guy, Laurent Morel, Jean-Marc Lobaccaro i Silvère Baron. "Lxrα Regulates the Androgen Response in Prostate Epithelium". Endocrinology 153, nr 7 (30.04.2012): 3211–23. http://dx.doi.org/10.1210/en.2011-1996.

Pełny tekst źródła
Streszczenie:
Benign prostatic hyperplasia is a nonmalignant enlargement of the prostate that commonly occurs in older men. We show that liver X receptor (Lxr)-α knockout mice (lxrα−/−) develop ventral prostate hypertrophy, correlating with an overaccumulation of secreted proteins in prostatic ducts and an alteration of vesicular trafficking in epithelial cells. In the fluid of the lxrα−/− prostates, spermine binding protein is highly accumulated and shows a 3000-fold increase of its mRNA. This overexpression is mediated by androgen hypersensitivity in lxrα−/− mice, restricted to the ventral prostate. Generation of chimeric recombinant prostates demonstrates that Lxrα is involved in the establishment of the epithelial-mesenchymal interactions in the mouse prostate. Altogether these results point out the crucial role of Lxrα in the homeostasis of the ventral prostate and suggest lxrα−/− mice may be a good model to investigate the molecular mechanisms of benign prostatic hyperplasia.
Style APA, Harvard, Vancouver, ISO itp.
2

G., Diamantis, i Tode V. "Consideration of Drug Therapy in Benign Prostatic Hypertrophy". ARS Medica Tomitana 20, nr 3 (31.01.2015): 129–34. http://dx.doi.org/10.2478/arsm-2014-0023.

Pełny tekst źródła
Streszczenie:
Abstract Benign prostatic hypertrophy (BPH) has become a major global health problem both in its frequency by which it determines the complications and the problems of diagnosis and treatment it requires. BPH is a heterogeneous disease. The symptoms attributed to BPH may have other coexisting causes and growth factors both androgen-dependent and independent, which promotes prostate enlargement. It is well known that prostate size correlates poorly with the symptoms so that reducing prostate using 5-alphareductase or alphablocants inhibitors may not always be sufficient. A better understanding of the pathophysiology of BPH and its interactions with other drugs will help the development of new substances with a better efficiency. This present work aims to be a modest contribution related to medical treatment in benign prostatic hyperplasia and the role that the generalist practitioner should play in managing of this urinary disease quite common in elderly men.
Style APA, Harvard, Vancouver, ISO itp.
3

Li, Peng-Long, Hui Liu, Guo-Peng Chen, Ling Li, Hong-Jie Shi, Hong-Yu Nie, Zhen Liu i in. "STEAP3 (Six-Transmembrane Epithelial Antigen of Prostate 3) Inhibits Pathological Cardiac Hypertrophy". Hypertension 76, nr 4 (październik 2020): 1219–30. http://dx.doi.org/10.1161/hypertensionaha.120.14752.

Pełny tekst źródła
Streszczenie:
Pathological cardiac hypertrophy is one of the major predictors and inducers of heart failure, the end stage of various cardiovascular diseases. However, the molecular mechanisms underlying pathogenesis of pathological cardiac hypertrophy remain largely unknown. Here, we provided the first evidence that STEAP3 (Six-Transmembrane Epithelial Antigen of Prostate 3) is a key negative regulator of this disease. We found that the expression of STEAP3 was reduced in pressure overload-induced hypertrophic hearts and phenylephrine-induced hypertrophic cardiomyocytes. In a transverse aortic constriction-triggered mouse cardiac hypertrophy model, STEAP3 deficiency remarkably deteriorated cardiac hypertrophy and fibrosis, whereas the opposite phenotype was observed in the cardiomyocyte-specific STEAP3 overexpressing mice. Accordingly, STEAP3 significantly mitigated phenylephrine-induced cell enlargement in primary neonatal rat cardiomyocytes. Mechanistically, via RNA-seq and immunoprecipitation-mass screening, we demonstrated that STEAP3 directly bond to Rho family small GTPase 1 and suppressed the activation of downstream mitogen-activated protein kinase-extracellular signal-regulated kinase signaling cascade. Remarkably, the antihypertrophic effect of STEAP3 was largely blocked by overexpression of constitutively active mutant Rac1 (G12V). Our study indicates that STEAP3 serves as a novel negative regulator of pathological cardiac hypertrophy by blocking the activation of the Rac1-dependent signaling cascade and may contribute to exploring effective therapeutic strategies of pathological cardiac hypertrophy treatment.
Style APA, Harvard, Vancouver, ISO itp.
4

Merendino, Rosaria Alba, Francesco Salvo, Antonella Saija, Giuseppe Di Pasquale, Antonio Tomaino, Paola Lucia Minciullo, Giuseppe Fraccica i Sebastiano Gangemi. "Malondialdehyde in benign prostate hypertrophy: a useful marker?" Mediators of Inflammation 12, nr 2 (2003): 127–28. http://dx.doi.org/10.1080/0962935031000097745.

Pełny tekst źródła
Streszczenie:
Benign prostate hypertrophy (BPH) is the most common benign tumor in men due to obstruction of the urethra and, finally, uremia. Malondialdehyde (MDA) is a product derived from peroxidation of polyunsaturated fatty acids and related esters. Evaluation of MDA in serum represents a non-invasive biomarker of oxidative stress. Prostate-specific antigen (PSA) is a sensitive marker for prostatic hypertrophy and cancer. We analyzed MDA serum levels to evaluate the oxidative stress in BPH. To this end, 22 BPH patients and 22 healthy donors were enrolled. Data show an increase of MDA level in BPH patients and a positive correlation between PSA and MDA levels. In conclusion, we describe a previously unknown relationship between PSA and MDA as an index of inflammation and oxidative stress in BPH.
Style APA, Harvard, Vancouver, ISO itp.
5

Nath, Chandan Kumar, Bhupen Barman, Pranjal Phukan, Stephen L. Sailo, Biswajit Dey, Indrajit Nath i Purnima Rajkhowa. "Prostate-Specific Antigen Density: A Measurement to Differentiate Benign Hypertrophy of Prostate from Prostate Carcinoma". Journal of Laboratory Physicians 12, nr 01 (marzec 2020): 44–48. http://dx.doi.org/10.1055/s-0040-1714195.

Pełny tekst źródła
Streszczenie:
Abstract Background Determination of isolated prostate-specific antigen (PSA) in asymptomatic individuals has not demonstrated sufficient sensitivity and specificity to be useful in the routine evaluation of prostate disease. To enhance the accuracy of serum PSA we have used a proportion of serum PSA and prostate volume, which we refer to as prostate-specific antigen density (PSAD). Prostate volume in this study was calculated using transrectal ultrasonography (TRUS). Materials and Methods A total of 106 patients with prostatic disease clinically confined to the prostate glands were evaluated. Results and Observation The mean PSAD for prostate cancer was 0.15 ± 0.01 while that for benign hypertrophy of the prostate (BPH) was 0.11 ± 0.02 (p < 0.05). Significant difference (p < 0.05) was noted in the prostate volume in these two groups with the mean prostate volume measured by TRUS in the BPH to be 53.85 ± 9.71 mL compared with 58.14 ± 7.48 mL in the carcinoma. PSA density of 0.13 ng/mL can be used as a cutoff for the individual in our set-up who should go for prostate biopsy with sensitivity and specificity of over 90%. Conclusion These results suggest that PSAD may be useful in distinguishing BPH and prostate cancer.
Style APA, Harvard, Vancouver, ISO itp.
6

Panarisi, S., M. Barbera, C. Cammarata, Q. Paola, G. Solazzo, F. Curto i G. Curto. "Mini-invasive treatment of BPH with TUIP". Urologia Journal 65, nr 1 (luty 1998): 137–39. http://dx.doi.org/10.1177/039156039806500135.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Gnana, Bhushan Kumar, i Sanjeeva Rao Matlapudi. "A comparative clinical evaluation of outcome of medical and surgical management of symptoms due to benign prostatic hyperplasia". International Surgery Journal 7, nr 9 (27.08.2020): 3032. http://dx.doi.org/10.18203/2349-2902.isj20203789.

Pełny tekst źródła
Streszczenie:
Background: Benign hypertrophy of prostate is common disorder and benign neoplasm of man above 50 years of age. Around 30% patients with benign hypertrophy of prostate lower urinary tract symptoms (LUTS) but all symptoms may not be due to benign hypertrophy of prostate (BHP). Present study has been designed for comparative evaluation of the outcome of medical and surgical management of symptoms, due to benign prostatic hyperplasia by using IPSS (international prostate score) and quality of life score as tool.Methods: In present study patients with LUTS, clinically diagnosed by per rectal digital examination and transrectal ultrasonographically confirmed cases of enlargement of prostate are enrolled for this study. Patients enrolled were divided equally in three groups.Results: After six month the mean IPSS score in silodosin (Sd) group was 6.55±0.86 and in Sd+Dutasteride (Dt) group it was 5.09±1.12. After six months mean IPSS score in Sd+Dt group was 5.09±1.12 and in TURP group it was 2.44±0.59.Conclusions: Single drug treatment with silodosin is associated with slow and less improvement in IPSS score in comparison with silodosin and dutasteride. But the response to TURP was better and faster than medical management.
Style APA, Harvard, Vancouver, ISO itp.
8

Zambolin, T., A. Cozzoli, G. Cancarini, G. P. Da Pozzo, C. Simeone, M. Scanzi, L. Tralce, F. Pagani i S. Cosciani-Cunico. "Correlation between benign prostatic hypertrophy (BPH) and prostatic antigen (PSA)". Urologia Journal 59, nr 1_suppl (styczeń 1992): 48–50. http://dx.doi.org/10.1177/039156039205901s15.

Pełny tekst źródła
Streszczenie:
PSA is a glycoprotein, which is present in both normal and pathological prostatic tissue, so it can be detected in the serum of patients with a normal prostate, BPH or prostatic cancer (PC). BPH and PC have the highest clinical incidence in the same agevange. The exact role of hypertrophic tissue in the variations of PSA serum levels must be determined when utilizing it as a tumoral marker of prostatic cancer. In order to determine it we matched serum PSA levels and prostate weight in 61 patients with BPH, proved by histological examination. Only in one case the value was higher than 20 ng/ml. So, in our opinion this value is the cut off. If the adenoma weight is 25–30 g or more, rectal examination and echography are normal, a biopsy is mandatory.
Style APA, Harvard, Vancouver, ISO itp.
9

Zattoni, F. "Benign Prostatic Hypertrophy, Prostatic Cancer and Preneoplastic Lesions". Urologia Journal 59, nr 1 (luty 1992): 58–60. http://dx.doi.org/10.1177/039156039205900113.

Pełny tekst źródła
Streszczenie:
Quite recently two dysplastic lesions have been found in prostatic tissue: atypical hyperplasia (AH), found in the periurethral zone, and prostatic intraepithelial neoplasia (PIN), present in the peripheral zone of the prostate. These lesions are likely to be considered as preneoplastic lesions. Theoretically they could be interpreted as the link between normal prostatic tissue and the cancer. It has also been suggested that BPH possibly contributes to the carcinogenetic process due to the demonstrated modifications occuring in the hyperplastic gland.
Style APA, Harvard, Vancouver, ISO itp.
10

Kuriyama, Manabu. "Prostate-Specific Antigen in Prostate Cancer". International Journal of Biological Markers 1, nr 2 (maj 1986): 67–76. http://dx.doi.org/10.1177/172460088600100202.

Pełny tekst źródła
Streszczenie:
Prostate-specific antigen (PA) has been evaluated clinically as a tumor marker of prostate cancer with the use of enzyme immunoassay (EIA). For serodetection of prostate cancer, PA was assayed in a total of 1,109 sera. From mean ± 3 S.D. of normal controls, upper cut-off values in males were decided as 2.5 and 1.2 ng/ml in Americans and Japanese, respectively. Serum PA values in prostate cancer patients were positive in 78% of Americans and 62% of Japanese. However, in benign prostatic hypertrophy (BPH) cases, a high false positive rate of 41% was observed in Americans. Simultaneous assays of serum PA and PAP showed high sensitivity and specificity in the detection of prostate cancer. This antigen could be used, as well as PAP, for monitoring prostate cancer patients. Furthermore, serum PA levels prior to treatment may express to some degree the malignant potential of the cancer. These results suggest that PA may be useful as a tumor marker of prostate cancer.
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Prostate – Hypertrophy"

1

Chang, Ching-Jey George. "Prostate, benign hypertrophy and prostatic carcinoma - a study of cell biology of prostate and chemotherapy for prostatic hypertrophy and prostatic cancer /". The Ohio State University, 1994. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487856906256116.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Herrera, Maria Lourdes C. "The expression of various growth factors in the normal human prostate, benign prostatic hyperplasia, and prostate carcinoma". Thesis, Hong Kong : University of Hong Kong, 1996. http://sunzi.lib.hku.hk/hkuto/record.jsp?B1754628X.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Viennois, Emilie. "Impact d'une invalidation de LXRα sur la physiologie prostatique : un dialogue avec la signalisation androgénique". Phd thesis, Université Blaise Pascal - Clermont-Ferrand II, 2011. http://tel.archives-ouvertes.fr/tel-00841380.

Pełny tekst źródła
Streszczenie:
L'hypertrophie bénigne de la prostate (HBP) est une pathologie qui affecte 50% des hommes dès l'âge de 60 ans et qui conduit à des troubles de la miction. L'HBP se caractérise par une hypertrophie exclusive ou composite de plusieurs compartiments tissulaires de la prostate que sont l'épithélium, le stroma et les fibres musculaires qui définissent respectivement les composantes glandulaire, fibreuse et musculaire de cette pathologie. Il a récemment été montré que les souris dépourvues en récepteurs nucléaires LXR (Liver‐X‐receptor) α (souris lxrα‐/‐) développent une hypertrophie de la prostate dont les signes histologiques évoquent une HBP de type fibreuse. Par ailleurs, un des traitements de l'HBP, vise à éteindre la signalisation androgénique en inhibant la conversion de la testostérone en son métabolite actif, la dihydrotestostérone (DHT). Le phénotype d'hypertrophie de la prostate pourrait donc également s'expliquer par une altération de la signalisation androgénique dans les souris lxrα‐/‐. Dans ce contexte, notre projet de recherche a été centré sur l'étude du rôle des LXR dans l'apparition de l'HBP dans sa composante glandulaire et l'analyse des relations moléculaires associant les signalisations dépendantes de LXRα et du récepteur des androgènes (AR) au sein de la prostate. Le phénotype d'HBP observé dans les souris lxrα‐/‐ résulte d'altérations importantes de l'homéostasie de l'épithélium qui miment la composante glandulaire : 1) une activité sécrétoire accrue ; 2) une altération des processus de sécrétion associée à une altération de l'expression des gènes codant des protéines du transport vésiculaire ; 3) une réponse altérée de certains gènes androgéno‐dépendants associée à une hypersensibilité aux androgènes ; 4) des modifications du réseau paracrine reliant le stroma et l'épithélium. Au final, ces travaux définissent LXRα comme un acteur clé de l'homéostasie prostatique et ouvrent des pistes intéressantes pour la compréhension de l'étiologie de l'HBP chez l'homme. Ces résultats montrent qu'il est possible de moduler la réponse androgénique de la prostate en ciblant LXRα. Ainsi, à plus long terme, l'activation pharmacologique de LXRα constitue une piste potentielle dans le traitement de l'HBP.
Style APA, Harvard, Vancouver, ISO itp.
4

Ambrosini, Gina L. "Dietary risk factors for prostate cancer and benign prostatic hyperplasia". University of Western Australia. School of Population Health, 2008. http://theses.library.uwa.edu.au/adt-WU2008.0135.

Pełny tekst źródła
Streszczenie:
[Truncated abstract] This thesis examines the potential role of dietary intake in the development of two common conditions affecting the prostate gland; prostate cancer and benign prostatic hyperplasia (BPH). Diet is of interest as a potential risk factor for prostate cancer because of geographical variations in prostate cancer incidence and increased prostate cancer risks associated with migration from Asian to western countries. Some geographical variation has been suggested for BPH, but this is less certain. However, both prostate cancer and BPH have potential links with diet through their positive associations with sex hormone levels, metabolic syndrome, increased insulin levels and chronic inflammation. In addition, zinc is an essential dietary micronutrient required for semen production in the prostate gland. The original work for this thesis is presented in six manuscripts of which, four have been published in peer-reviewed journals (at the time of thesis completion). BPH investigated in this thesis is defined as surgically-treated BPH. The following hypotheses were investigated. Regarding foods, nutrients and the risk of prostate cancer and BPH: 1. Increasing intakes of fruits, vegetables and zinc are inversely associated with the risk of prostate cancer and BPH 2. Increasing intakes of total fat and calcium are positively associated with the risk of prostate cancer and BPH. 3. Dietary patterns characterised by high meat, processed meat, calcium and fat content are positively associated with the risk of prostate cancer and BPH. 4. Dietary patterns characterised by high fruit and vegetable and low meat content are inversely associated with the risk of prostate cancer and BPH. v Regarding methodological issues related to the study of diet-disease relationships: 5. Dietary patterns (overall diet) elicited from principal components analysis yield stronger diet-disease associations than when studying isolated nutrients. 6. Remotely recalled dietary intake is reliable enough to be used in studies of chronic disease with long latency periods, such as prostate cancer and BPH. Methods: Data from two studies was used to address the hypotheses above. ... Based on the literature reviewed and the original work for this thesis, the most important dietary risk factors for prostate cancer and BPH appear to be those common to western style diets, i.e. diets high in red meat, processed meat, refined grains, dairy products, and low in fruit and vegetables. This type of diet is likely to result in marginal intakes of antioxidants and fibre, excess intakes of fat and possibly, moderate intakes of carcinogens associated with processed meat and meat cooked at high temperatures. These dietary factors have been linked with biomarkers of inflammation, and they support the hypotheses that chronic inflammation is involved in the development of both prostate cancer and BPH. In addition, this work builds on evidence that zinc is an important factor in prostate health. There is scope for more investigation into the reliability of dietary patterns and the use of nutrient patterns as an alternative to focussing on single food components. Further studies on the reliability of remote dietary intake would also be useful. Because of the latency of chronic disease, it can be theorised that remote dietary recall may uncover more robust diet-disease relationships.
Style APA, Harvard, Vancouver, ISO itp.
5

Smith, Carolyn Margaret. "Characterisation of androgen metabolism and 5α-reductase activity in human prostate cells in vitro". Thesis, University College London (University of London), 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.308889.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Lima, Junior Mario Maciel de 1974. "Analise do perfil genotipico do sistema glutationa S-transferase e citocromo P450 na avaliação de susceptibilidade ao cancer de prostata e de prognostico". [s.n.], 2006. http://repositorio.unicamp.br/jspui/handle/REPOSIP/310275.

Pełny tekst źródła
Streszczenie:
Orientador: Laura Sterian Ward
Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas
Made available in DSpace on 2018-08-06T20:05:49Z (GMT). No. of bitstreams: 1 LimaJunior_MarioMacielde_M.pdf: 2114915 bytes, checksum: 56c9d6904dd7e0a16ab5565b0d280b7c (MD5) Previous issue date: 2006
Resumo: O câncer de próstata (CaP) é atualmente a neoplasia maligna mais prevalente no mundo, após os tumores de pele. A incidência dessa enfermidade tem crescido nas últimas décadas devido, principalmente; ao aumento da longevidade da população. Atualmente o CaP tem sido detectado em estágios menos avançados do que no passado. As melhorias dos métodos de diagnóstico contribuem para a detecção precoce dessa neoplasia. Os polimorfismos de genes que codificam enzimas envolvidas na metabolização de drogas e de xenobióticos, como as do sistema Glutationa S-transferase (GST) e Citocromo P450 (CYP), podem estar implicados no risco e prognóstico para neoplasias. Foram avaliados os genótipos de GSTT1, GSTM1, GSTP1, GSTO1 e CYP1A1 em 125 pacientes portadores de câncer de próstata e em 100 indivíduos com hiperplasia prostática benigna. Tempo e atividade ocupacional, tabagismo e outros dados relevantes da história natural da doença foram obtidas por meio de entrevistas. Não foram encontrados quaisquer associações entre os genótipos estudados e o risco de câncer de próstata, tanto avaliando os diferentes genótipos em separado como em combinações, através de análise de regressão logística uni ou multivariada. Não houve associação entre os genótipos estudados e fatores clínicos de risco para câncer de próstata ou quaisquer parâmetros de agressividade do tumor ao diagnóstico ou durante o seguimento. Nossos dados permitem concluir que os genótipos de GST e CYP1A1 não estão associados à susceptibilidade ao câncer de próstata ou à sua evolução na população brasileira estudada
Abstract: Prostate cancer is currently the most common malignancy worldwide, second only to skin tumors. The incidence of prostate cancer has risen dramatically over the last decade, more than can be explained just by the increase in longevity. It is also apparent that prostate cancer is now being detected at less advanced stages than in the past. Increased awareness of the disease and improved detection methods are thought to contribute to this earlier detection. The polymorphic inheritance of human drug-metabolizing enzymes, such as those encoded by the Glutathione-S-Transferase (GST) and the Cytochrome P450 (CYP) systems, may be implicated in both cancer risk and prognostic. We compared GSTT1, GSTM1, GSTO1, GSTP1 e CYP1A1 genotypes of 125 prostate cancer and 100 benign prostatic hyperplasia patients. Lifetime occupational history, cigarette-smoking, and other anamnestic data were obtained through interviews. None of the studied polymorphisms was found associated to prostate cancer risk either considered in separate or in combination, in uni ou multivariate regression logistic analysis. Also, there was no association between genotypes and possible clinical factors of risk, or any parameter of tumor agressiveness at diagnosis or during follow-up. Our data suggest that GST and CYP1A1 genotypes are not associated to the susceptibility to prostate cancer or its outcome in the Brazilian population
Mestrado
Clinica Medica
Mestre em Clinica Medica
Style APA, Harvard, Vancouver, ISO itp.
7

Tsang, K. K. "Screening for benign prostatic hypertrophy". Thesis, University of Edinburgh, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.663068.

Pełny tekst źródła
Streszczenie:
Benign prostatic hypertrophy (BPH) is a very common disease among men aged 50 and its economic burden on health services continues to grow. The advocation for adopting new screening procedure for BPH begins to emerge. However, a new proposal for screening should be under careful scrutiny and ineffective and inappropriate screening must be avoided. A prospective cohort study has been launched to study the frequency, distribution, and natural history of BPH in two well-defined small communities in Central Scotland. Using the data from the cohort study, the hypothesis that a BPH screening programme justifies the stringent criteria set by Wilson and Jungner (1968) to evaluate any proposed programme, could be tested. The hypothesis has to be rejected after taking all the criteria into account. BPH was a major health problem among apparently well middle-age and elderly men in the community. It imposed significant interference in men's daily routine as well as influenced on their psychological general well-being. Although there was a detectable asymptomatic stage, the natural history of BPH from asymptomatic to a clinical stage was not clear. Because of the obscurity of the natural history, the optimum interval between repeated screens of a continuous screening process was unknown. The facilities for diagnosis and treatment could not be met by the present health services. The economic implications of a screening programme could be enormous, though a systemic analysis to evaluate the worthwhileness of the screening programme in economic terms was not conducted.
Style APA, Harvard, Vancouver, ISO itp.
8

COEURDACIER, PIERRE. "Resultats a long terme de la chirurgie pour hypertrophie benigne de prostate". Rennes 1, 1993. http://www.theses.fr/1993REN1M027.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Ahouandjinou, Theodora Vignon. "Facteurs nutritionnels associés à la présence de lésions précancéreuses de la prostate (PIN) chez des hommes ayant une hypertrophie bénigne de la protestate". Master's thesis, Université Laval, 2008. http://hdl.handle.net/20.500.11794/19946.

Pełny tekst źródła
Streszczenie:
La néoplasie intra-épithéliale prostatique, un des précurseurs possibles du cancer de la prostate, pourrait donner des renseignements sur les causes de ce dernier dans la mesure où ils cohabitent souvent. Dans une étude transversale, réalisée chez 510 hommes traités chirurgicalement pour une hypertrophie bénigne de la prostate, nous avons testé l'hypothèse que les facteurs de risque souvent associés au cancer de la prostate pouvaient être aussi associés à la présence de la néoplasie intra-épithéliale prostatique. La consommation alimentaire au cours de l'année précédant la chirurgie a été documentée par un questionnaire alimentaire détaillé administré par une diététiste. Le tissu prostatique prélevé à la chirurgie a été examiné par un seul pathologiste. Seuls les patients ayant une hypertrophie bénigne et aucune évidence de cancer ont été retenus pour l'étude. La présence de lésions précancéreuses de la prostate (PIN) a été observée chez 81 participants. La majorité des analyses a porté sur les relations entre les facteurs nutritionnels suspectés de jouer un rôle dans le cancer de la prostate et la présence de PIN. Les rapports de cotes ajustés (RC) et leurs intervalles de confiance (IC à 95%) ont été estimés à l'aide de la régression logistique pour les différentes variables des apports alimentaires. Les résultats sont pour la majorité non statistiquement significatifs, seule une importante consommation de carottes avec un RC, comparant le 3ème au premier tercile, de 1,84 (IC à 95% =1,00-3,40), et d'alpha-carotène avec un RC = 1,90 (IC à 95% =1,04-3,45) sont statistiquement significatifs. En regard du nombre d'associations évaluées ces résultats ne suggèrent aucune association entre les facteurs nutritionnels associés au cancer de la prostate et la présence de PIN.
Style APA, Harvard, Vancouver, ISO itp.
10

DUCHEMIN, JEAN-MICHEL. "Place de l'adenomectomie retro-pubienne dans le traitement chirurgical de l'hypertrophie benigne de la prostate". Amiens, 1994. http://www.theses.fr/1994AMIEM090.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Prostate – Hypertrophy"

1

Ayurvedic managment of benign prostate hypertrophy. Colombo, Sri Lanka: S. Godage & Brothers (Pvt) Ltd., 2014.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

1952-, Norman Richard W., Canadian Medical Association i Canadian Prostate Health Council, red. A prostate problem: Benign prostatic hyperplasia : a physician's guide to care and counselling. Montréal: Grosvenor House Press, 1993.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Cunningham, Chet. Your prostate: What every man over 40 needs to know....NOW! Wyd. 2. Leucadia, Calif: United Research Publishers, 1992.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Chet, Cunningham, i Chet Cunningham. Your prostate: What every man over 40 needs to know-- now! Leucadia, Calif: United Research Publishers, 1990.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Kathleen, Doheny, red. The well-informed patient's guide to prostate problems. New York: Dell, 1993.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

H, Schröder F., red. Recent advances in prostate cancer and BPH: The proceedings of the IV Congress on Progress and Controversies in Oncological Urology (PACIOU IV), held in Rotterdam, the Netherlands, April 1996. New York: Parthenon, 1997.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Kyoichi, Imai, Shimazaki Jun i Karr James P, red. Fundamental approaches to the diagnosis & treatment for prostate cancer and BPH: Proceedings of the Fifth Tokyo Symposium on Prostate Cancer, December 16-17, 1993, Keidanren-Kaikan, Tokyo, Japan. Schenectady, NY, USA: Adenine Press, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Honma, Yukio. Subete wakaru!! zenritsusen gan, hidaishō. Tōkyō: Mainichi Shinbunsha, 2005.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

She hu xian fei da. Taibei Xian Shenkeng Xiang: Yuan lu shu she, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Parker, Philip M., i James N. Parker. Enlarged prostate: A medical dictionary, bibliography, and annotated research guide to Internet references. San Diego, CA: ICON Health Publications, 2004.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Prostate – Hypertrophy"

1

Order, Stanley E., i Sarah S. Donaldson. "Benign Prostate Hypertrophy". W Radiation Therapy of Benign Diseases, 44. Berlin, Heidelberg: Springer Berlin Heidelberg, 2003. http://dx.doi.org/10.1007/978-3-642-58719-1_23.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Hoffman, Robert M. "Clinical Usefulness of the Histoculture Drug Response Assay for Prostate Cancer and Benign Prostate Hypertrophy (BPH)". W 3D Sponge-Matrix Histoculture, 101–7. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7745-1_11.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Scattoni, Vincenzo, i Carmen Maccagnano. "Benign Prostatic Hypertrophy". W Atlas of Ultrasonography in Urology, Andrology, and Nephrology, 281–91. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-40782-1_23.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Mebust, W. K. "Benign Prostatic Hypertrophy: Standards and Guidelines". W Alternate Methods in the Treatment of Benign Prostatic Hyperplasia, 26–44. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-45723-4_3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Sullivan, M. P., i S. V. Yalla. "Urodynamic Assessment of Benign Prostatic Hypertrophy". W Alternate Methods in the Treatment of Benign Prostatic Hyperplasia, 66–89. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-45723-4_5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Stone, N. N. "Flutamide and Aromatase Inhibitors in Benign Prostatic Hypertrophy". W Alternate Methods in the Treatment of Benign Prostatic Hyperplasia, 183–93. Berlin, Heidelberg: Springer Berlin Heidelberg, 1993. http://dx.doi.org/10.1007/978-3-642-45723-4_12.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Lomas, Derek J., i Amy Krambeck. "Surgical management of lower urinary tract symptoms secondary to benign prostatic hypertrophy". W Evidence-Based Urology, 527–37. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119129875.ch46.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Simon, Chantal, Hazel Everitt, Françoise van Dorp i Matt Burkes. "Renal medicine and urology". W Oxford Handbook of General Practice, 435–70. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199671038.003.0014.

Pełny tekst źródła
Streszczenie:
Creatinine, urea, and electrolytes Presentation of renal disease Renal failure Kidney diseases Renal stones Haematuria, bladder and renal cancer Urinary tract infection Incontinence of urine Aids and appliances for incontinence Urinary tract obstruction Benign prostatic hypertrophy Prostate cancer Treatment of prostate cancer Conditions of the penis...
Style APA, Harvard, Vancouver, ISO itp.
9

Shaw, Aidan, Irfan Ahmed i Tarun Sabharwal. "Prostate artery embolization for benign prostate hypertrophy". W Challenging Concepts in Interventional Radiology and Endovascular Procedures, 195–200. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199664382.003.0023.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

"PROSTATIC HYPERTROPHY AND CANCER OF THE PROSTATE". W General Practice for Lawyers, 209–16. Routledge-Cavendish, 1996. http://dx.doi.org/10.4324/9781843143604-24.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Prostate – Hypertrophy"

1

Gomella, Leonard G., M. A. Lotfi, Douglas F. Milam, David Albala i Gary Reagan. "Contact laser vaporization of the prostate for benign prostatic hypertrophy". W OE/LASE '94, redaktorzy Graham M. Watson, Rudolf W. Steiner i Douglas E. Johnson. SPIE, 1994. http://dx.doi.org/10.1117/12.175023.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Walendziuk, Wojciech, Aleksander Sawicki i Adam Idźkowski. "The supporting method for automatic diagnosis of prostatic hypertrophy". W Biomdlore. VGTU Technika, 2016. http://dx.doi.org/10.3846/biomdlore.2016.13.

Pełny tekst źródła
Streszczenie:
In the paper numerical algorithms used in the automatic diagnosis of prostatic hypertrophy are presented. The liquid flow during urination was applied as a signal that describes the condition of prostate. In order to register the signal, the uroflowmeter was used. Patients were included in a two-step procedure. In the first step, an analysis of signal characteristics, such as maximum and the mean value with the use of Liverpool Nomogram, were performed. Then, the signal was tested for the presence of oscillation. For this purpose, an algorithm that generates the reference signal was created. Moreover, the similarity waveform was investigated with the help of the integral index. The diversity of signals indicated the presence of anomalies and had an impact on the final classification of the patient.
Style APA, Harvard, Vancouver, ISO itp.
3

Muschter, Rolf, Alfons G. Hofstetter, Stefan F. F. Hessel, Ernst Keiditsch, Karl-Heinz Rothenberger, Peter Schneede i Klaus H. Frank. "Hi-tech of the prostate: interstitial laser coagulation of benign prostatic hypertrophy". W OE/LASE '92, redaktor R. R. Anderson. SPIE, 1992. http://dx.doi.org/10.1117/12.137385.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Wu, Jianchun, i David L. Crowe. "Abstract 1464: Telomere DNA damage links benign prostatic hypertrophy, intraepithelial neoplasia, and prostate cancer". W Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1464.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Tanaka, Mami, Mitsuyuki Furubayashi, Yoshikatsu Tanahashi i Seiji Chonan. "Active palpation sensor for detecting prostatic cancer and hypertrophy". W Smart Materials and MEMS, redaktorzy Dinesh K. Sood, Ronald A. Lawes i Vasundara V. Varadan. SPIE, 2001. http://dx.doi.org/10.1117/12.420885.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Prostate – Hypertrophy” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii